Asthma Drug Co-Developed by Dynavax and AstraZeneca Fails to Meet Endpoints in Phase IIa Trial

Shares of Dynavax Technologies Corporation fell more than 5 percent in Thursday’s trading and is continuing to fall in premarket trading after the company reported that an asthma drug it is co-developing with AstraZeneca failed to meet endpoints in a mid-stage trial.